Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Predict branded drug patent expiration
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 4,839,177

« Back to Dashboard

Summary for Patent: 4,839,177

Title: System for the controlled-rate release of active substances
Abstract:A system for the controlled-rate release of active substances, consisting of: (a) a deposit-core comprising the active substance and having defined geometric form; (b) a support-platform applied to said deposit-core. Said deposit-core contains, mixed with the active substance, a polymeric material having a high degree of swelling on contact with water or aqueous liqids, a gellable polymeric material, said polymeric materials being replaceable by a single polymeric material having both swelling and gelling properties, and other adjuvants able to provide the mixture with suitable characteristics for its compression and for its intake of water.
Inventor(s): Colombo; Paolo (Pavia, IT), La Manna; Aldo (Pavia, IT), Conte; Ubaldo (Busto Arsizio, IT)
Assignee: Jagotec AG (Hergiswill, CH)
Application Number:06/939,810
Patent Claim Types:
see list of patent claims
Formulation; Process;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,839,177

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Italy23321 A/85Dec 20, 1985

International Patent Family for Patent: 4,839,177

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria58472► Subscribe
Australia594992► Subscribe
Australia6672586► Subscribe
Canada1298479► Subscribe
Germany3675748► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.